
Henry Schein (HSIC) Stock Forecast & Price Target
Henry Schein (HSIC) Analyst Ratings
Bulls say
Henry Schein Inc. demonstrated a positive growth trajectory, with dental business revenue increasing by 6.2% and adjusted EBITDA anticipated to grow by a mid-single-digit percentage, reflecting strong operational performance. The global technology segment also contributed positively with reported revenue of $160 million and a growth rate of 2.4%, indicating a robust demand for healthcare solutions. Furthermore, the company's outlook for non-GAAP EPS, projected between $4.80-4.94, combined with expectations for accelerated earnings growth post-2025, reinforces a favorable financial outlook.
Bears say
Henry Schein Inc. reported disappointing fourth-quarter results, with total revenue of $3.19 billion, representing a growth of only 5.8%, which fell notably short of the anticipated $3.35 billion. The gross margin decreased to 31.1%, below the expected 31.6%, contributing to an earnings shortfall that reflects weak performance across the core distribution segment. Additionally, management indicated potential ongoing challenges tied to the transition to a SaaS model and adverse seasonal factors impacting both revenue growth and overall earnings outlook in the near term.
This aggregate rating is based on analysts' research of Henry Schein and is not a guaranteed prediction by Public.com or investment advice.
Henry Schein (HSIC) Analyst Forecast & Price Prediction
Start investing in Henry Schein (HSIC)
Order type
Buy in
Order amount
Est. shares
0 shares